Researchers develop promising method for delivering HIV-fighting antibodies

February 10, 2014
Researchers develop promising method for delivering HIV-fighting antibodies
An illustration shows the crystal structure of the small virus used to deliver antibodies as vectored immunoprophylaxis against hiv. Credit: Alejandro Balazs / Caltech

(Medical Xpress)—In 2011, biologists at the California Institute of Technology (Caltech) demonstrated a highly effective method for delivering HIV-fighting antibodies to mice—a treatment that protected the mice from infection by a laboratory strain of HIV delivered intravenously. Now the researchers, led by Nobel Laureate David Baltimore, have shown that the same procedure is just as effective against a strain of HIV found in the real world, even when transmitted across mucosal surfaces.

The findings, which appear in the February 9 advance online publication of the journal Nature Medicine, suggest that the delivery method might be effective in preventing vaginal transmission of HIV between humans.

"The method that we developed has now been validated in the most natural possible setting in a mouse," says Baltimore, president emeritus and the Robert Andrews Millikan Professor of Biology at Caltech. "This procedure is extremely effective against a naturally transmitted strain and by an intravaginal infection route, which is a model of how HIV is transmitted in most of the infections that occur in the world."

The new delivery method—called Vectored ImmunoProphylaxis, or VIP for short—is not exactly a vaccine. Vaccines introduce substances such as antigens into the body to try to get the immune system to mount an appropriate attack—to generate that can block an infection or T cells that can attack infected cells. In the case of VIP, a small, harmless virus is injected and delivers genes to the muscle tissue, instructing it to generate specific antibodies.  

The researchers emphasize that the work was done in mice and that the leap from mice to humans is large. The team is now working with the Vaccine Research Center at the National Institutes of Health to begin clinical evaluation.

This video is not supported by your browser at this time.
Caltech biologists david baltimore and alejandro balazs discuss their novel approach to hiv prevention: a delivery method for neutralizing antibodies, which protect against hiv infection in mice. Credit: Caltech

Explore further: Biologists deliver neutralizing antibodies that protect against HIV infection in mice

More information: "Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission." Alejandro B Balazs, Yong Ouyang, Christin M Hong, Joyce Chen, Steven M Nguyen, Dinesh S Rao, Dong Sung An, David Baltimore. Nature Medicine (2014) DOI: 10.1038/nm.3471
Received 03 October 2013 Accepted 07 January 2014 Published online 09 February 2014

Related Stories

Durable end to AIDS will require HIV vaccine development

February 5, 2014

Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately ...

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.